Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
EAP1 CRISPR/Cas9 KO Plasmid (h): sc-408947
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EAP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EAP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: EAP1 Antibody (C-9): sc-514772
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EAP1 CRISPR/Cas9 KO Plasmid (h) | sc-408947 | 20 µg | $397.00 |
Overview
IRF2BPL encodes EAP1, a nuclear RING-finger protein implicated in transcriptional control and ubiquitin-dependent regulation of protein stability. EAP1 has been linked to modulation of gene expression programs that influence cell cycle progression, differentiation, and neuronal homeostasis, consistent with roles in proteostasis and stress-responsive signaling. Genetic disruption of IRF2BPL is associated with neurodevelopmental and neurodegenerative phenotypes, supporting its relevance to pathways governing neuronal maintenance and synaptic function. Accordingly, IRF2BPL/EAP1 is studied in mechanisms of transcriptional regulation, ubiquitination-linked turnover, and cellular resilience in human model systems.
EAP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IRF2BPL gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IRF2BPL together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IRF2BPL open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EAP1 protein expression.
This CRISPR knockout system enables efficient generation of IRF2BPL-deficient cell models for investigation of EAP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IRF2BPL exon(s) critical for EAP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IRF2BPL genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EAP1 CRISPR/Cas9 KO Plasmid (h) and EAP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IRF2BPL locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EAP1 HDR Plasmid (h) and EAP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IRF2BPL homology arms to support homology-directed repair at defined IRF2BPL target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.